At the European Association of Nuclear Medicine meeting, Monopar Therapeutics Inc. presented the preclinical characterization of MNPR-101, a first-in-class urokinase-type plasminogen activator ...

智通财经APP获悉，11 月 13 日，诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理。此前该药已被 CDE 纳入优先审评，适用于治疗前列腺特异性膜 ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...

Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specializing in developing antibody ...

To advance the development of next-generation antibody–conjugate drugs ... than Novartis’ approved radiopharmaceutical Pluvicto (177Lu-PSMA-617), despite using half the amount of lutetium ...

Dr. Scott Tagawa presented ProstACT GLOBAL, a phase III study of best SOC with or without 177 Lu-DOTA-rosopatamab (TLX591) for patients with PSMA-expressing mCRPC who experienced disease progression ...

(UroToday.com) The 2024 SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Eric Jonasch discussing a phase 1B/2 study of combination 177 Lu Girentuximab + ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price ...

Pluvicto (lutetium (177Lu) vipivotide tetraxetan) has been cleared for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with ...

The main function of RAD204 – a single domain monoclonal antibody – is its targeting ... supporting the potential of 177Lu-RAD204 for a tumor-agnostic indication and as an effective ...